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<ABSTRACT>
Assessment of Extracellular Volume Fraction Using Dual-energy CT in 
Doxorubicin-induced Dilated Cardiomyopathy in a Rabbit Model: 
Comparison with Contrast-enhanced Magnetic Resonance Imaging and 
Histology
Yoo Jin Hong
Department of Medicine 
The Graduate School, Yonsei University
Directed by Professor Byoung Wook Choi
Purpose:
To assess the feasibility of extracellular volume (ECV) fraction 
using dual-energy computed tomography (CT) and to compare it with 
magnetic resonance imaging (MRI) T1 mapping and histologic findings.
Materials and methods:
A dilated cardiomyopathy rabbit (DCR) model was made by 
injecting doxorubicin into the rabbits (adult male New Zealand white 
rabbits, 3-4 kg) at doses of 1.0 mg/kg twice a week. Every rabbit 
underwent both dual-energy CT and magnetic resonance imaging (MRI) 
within two hours with pre-/post-contrast T1 mapping using modified 
Look-Locker inversion recovery (MOLLI) sequence, late gadolinium 
enhancement (LGE), and cine MR on a clinical 3-T system. The rabbits 
underwent CT and MR examination before drug administration (control 
group) and DCR model at various post-modeling intervals (6 weeks, 12 
weeks or 16 weeks after DCR modeling). CT ECV was quantitatively 
assessed by measuring Hounsfield units (HUs) in the septum in a cardiac 
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short-axis view on iodine maps. MR ECV was assessed in the same area 
with CT. The left ventricle ejection fraction (LVEF) was obtained from the 
cine MR images using Simpson's method.
Results: 
Fifteen rabbits were scanned prior to modeling, and then four 
controls were sacrificed for histology. The remaining eleven underwent 
DCR modeling and were scanned at various post-modeling intervals (Group 
I; 6-week modeling, n = 11: group II; 12-week modeling, n = 8: and 
group III; 16-week modeling, n = 5). The mean CT ECV values (%) of 
group I-III were significantly higher than control group (Control vs. group I 
vs. group II vs. group III; 28.5 (range, 25.9-31.3) vs. 35.3 (range, 
30.2-40.1) vs. 41.9 (range, 35.6-44.1), vs. 42.1 (range, 39.2-46.4), p < 
0.001) and there was a good correlation between CT ECV and MR ECV 
(r = 0.888, p < 0.001) and between CT ECV and degree of fibrosis (r = 
0.811 p < 0.001)
Conclusion: 
ECV using dual-energy CT shows good correlation with MRI and 
histology. Noninvasive measurement of ECV in animals with 
doxorubicin-induced diffuse myocardial fibrosis is feasible with dual-energy 
CT without misregistration errors.

Key words: magnetic resonance imaging, endomyocardial fibrosis, 
extracellular space, extracellular matrix, radiography, dual-Energy scanned 
projection, multidetector computed tomography
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Assessment of Extracellular Volume Fraction Using Dual-energy CT in 
Doxorubicin-induced Dilated Cardiomyopathy in a Rabbit Model: 
Comparison with Contrast-Enhanced Magnetic Resonance Imaging and 
Histology
Yoo Jin Hong
Department of Medicine 
The Graduate School, Yonsei University
Directed by Professor Byoung Wook Choi
I. INTRODUCTION
 Diffuse myocardial fibrosis is a final common end point in the 
pathological process of myocardial disease.1,2 Diffuse myocardial fibrosis 
indicates irreversible damage to the myocardium. This insult to the 
myocardial structure is known to be associated with adverse cardiac events: 
heart failure, hospitalization, sudden death, etc. in various types of 
cardiomyopathy.3-5
Myocardial T1 mapping is an emerging technique that could 
improve detection of diffuse interstitial myocardial fibrosis using 
measurements of extracellular volume (ECV) fraction. ECV fraction can be 
used to quantitatively evaluate myocardial fibrosis and, subtle myocardial 
change in various cardiac diseases.1,6-9 ECV fraction has been demonstrated 
yielding a good correlation with histologic finding.10 A few recent studies 
reported that computed tomography (CT) utilizing iodine contrast was useful 
to detect diffuse myocardial fibrosis.11-13 Nacif et al. demonstrate in clinical 
practice the application of the theory of ECV fraction using iodine contrast 
agent in diffuse fibrosis patients based on the theory that iodine contrast 
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agents are also extracellular tracers having the same distribution area as 
gadolinium contrast agents.12-15 They used conventional CT with pre- and 
post-contrast CT scans. The ECV measured on CT scan correlated well 
with that of MRI.12,13
In a study of in vivo models by Gerber et al., contrast-enhanced 
CT characterized acute and chronic myocardial infarction with contrast 
patterns similar to contrast-enhanced magnetic resonance imaging (MRI). 
Their study demonstrated similar contrast kinetics and distribution pattern 
between an iodine and a gadolinium contrast agent in infarcted and 
noninfarcted myocardium.15 Gerber et al. suggested this may be due to 
these iodine and gadolinium tracers’ similar molecular weights and 
extracellular volume of distribution even though the tracers’ molecular 
structures were different.14,15 Due to the kinetic similarities between 
gadolinium agents used in MRI and iodine contrast agents used in CT 
there can be similar imaging applications. 
The general advantages of CT in comparison with MRI are faster, 
widely available, and cheaper imaging.11 The specific advantages of CT in 
the evaluation of the heart are the possibility of simultaneous evaluation of 
coronary arteries as well as the evaluation of whole myocardium. However, 
there are no prior reports on the quantification of the ECV using 
dual-energy CT in diffuse myocardial fibrosis patients. Dual-energy CT is 
an advanced imaging technique that can provide material composition 
information by using two data sets of different X-ray spectra.16 The major 
advantages of dual-energy CT over conventional CT in this study are to 
differentiate iodine component on delayed contrast-enhanced imaging without 
misregistration artifact. 
We hypothesized that dual-energy CT would be valuable for 
extracting the iodine component of the myocardium and assessing CT ECV. 
The purposes of this study were to validate ECV using dual-energy CT 
and to compare it with that of contrast-enhanced MRI and to access 
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histologic collagen volume fraction (CVF) in dilated cardiomyopathy rabbit 
models.
II. MATERIALS AND METHODS
1. Animal model and drug administration
  Twenty adult male New Zealand white rabbits weighing between 
3-4 kg were included in this study. Among them, four rabbits were not 
subjected to drug administration for the evaluation of histology as a control 
group. In the other rabbits, doxorubicin (Doxorubicin hydrochloride, Cayman 
Chemical, Ann Arbor, MI) was injected at doses of 1.0 mg/kg twice a 
week until they were sacrificed for histologic evaluation. The ear was 
clipped, the skin was sterilized, and the auricular vein was accessed by the 
introduction of a 21-gauge needle. The doxorubicin (1.0 mg/kg) was diluted 
with 20 ml 0.9% sterile saline. The diluted drug was slowly injected for 3 
minutes with bolus injection method. Antibiotics sulfamethoxypyridazine and 
trimethoprim (Amphoprim bolus; Virbac, New Zealand) were administered 
every day from 5 weeks after the DCR modeling began. Hematocrit (Hct) 
levels were measured immediately before the CT examinations.
2. Animal preparation before CT and MR examinations
The rabbits underwent CT and MR examination before drug 
administration (control group) and dilated cardiomyopathy rabbit (DCR) 
models at the end of post-modeling intervals (6 weeks, 12 weeks or 16 
weeks after DCR modeling). Before CT examination the rabbits were 
anaesthetized with an intra-muscular injection of tilematine (30mg/kg, 
Zoletil; Vibac Laboratories, Carros, France) and xylazine (5mg/kg, Rompun; 
Bayer, Korea), and the rabbits were shaved on the anterior chest wall for 
electrocardiographic (ECG) electrodes. Two venous accesses were prepared 
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at both auricular veins. The first venous access was used for contrast 
injection, and the second venous access was used for medetomidine 
hydrochloride (0.3mg/kg, Tomidine®; Provet verterinary products Ltd. 
Istanbul, Turkey) administration. Venous sampling was done for Hct values 
of all rabbits. After anesthesia, the animals were intubated, and 
mechanically ventilated using a mechanical ventilator (Mekant, MEKICS, 
Seoul, Korea) with a mixture of oxygen and isoflurane for CT and MR 
scanning. The ventilator was not MRI-compatible, so, it was located outside 
the MRI room with its long respiratory tubes entering the room through a 
hole in the wall.
3. Animal inclusion and a flow chart of experiment 
Twenty rabbits were included. Among them, four control rabbits 
were sacrificed after CT and MRI scanning for the histologic evaluation as 
a control group. The other sixteen rabbits were subjected to drug 
administration for DCR modeling. Five rabbits died during the modeling 
periods due to severe anemia (n = 3) or infection (pneumonia, n = 2). At 
the end of the 6-week modeling period, Group I (n = 11) underwent 
post-modeling CT and MRI scans. Afterwards 3 rabbits were sacrificed for 
the histologic evaluation at the 6-week modeling period. The other eight 
rabbits (Group II; n = 8) continued DCR modeling, and underwent 
post-modeling CT and MRI scans at the end of the 12-week modeling 
period. Next 3 rabbits were sacrificed for the histologic evaluation at the 
12-week modeling period. The other five rabbits continued DCR modeling 
(Group III; n = 5), and underwent post-modeling CT and MRI scans at the 
end of the 16-week modeling period. After post-modeling CT and MRI 
scanning, the five remaining rabbits were sacrificed for a histologic 
evaluation at the 16-week modeling period (Fig 1).
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Figure 1. Flow chart of experiment
4. CT protocol
Dual-energy CT was performed using a dual-source CT (Somatom 
Definition Flash, Siemens Healthcare, Forchheim, Germany) with 
retrospectively ECG-gated helical scanning without ECG pulsing. Scan 
parameters were as follows: 185 effective mAs at 100kV, and 157 effective 
mAs at 140 kV with a tin filter, 64 × 0.6 mm collimation, 0.32 pitch factor, 
and 0.28 second rotation time. Images were acquired from the apex of the 
heart to the costophrenic angles in the caudocranial direction. After bolus 
injection of 2 ml/kg contrast medium (Pamiray 370, Dongkook 
- 8 -
Pharmaceutical, Seoul, Korea) followed by 8-10 mL of normal saline at 
1.5-1.7 mL/s through the auricular vein of rabbits. The first post-contrast scan 
started at 3 minutes, and additional scans were done at 5, 7, 9, 11, 13 and 
20 minutes after the attenuation value reached 100 Hounsfield units (HUs) in 
the thoracic aorta using the bolus tracking technique. Each rabbit was given a 
bolus injection of 0.3 mg/kg of medetomidine to reduce heart rate 30 seconds 
before each scanning. 
5. Dual-energy CT data post processing 
CT data sets were assessed by two radiologists (Y.J.H., C.H.P.) 
with more than nine years of experience in cardiac CT. All scans were 
processed and read on a dedicated workstation equipped with dual-energy 
post processing software (Syngo MMWP VE 36A, Siemens Medical 
Solutions, Forchheim, Germany). The weighted average image was 
approximately 120 kV and was automatically generated from a combination 
of the 140 kV and 100 kV data. Dual-energy post processing was 
performed with the heart perfusion application (Siemens dual-energy 
software. First an image-based analysis was run with the low-energy and 
high-energy images. Next iodine maps were created based on a 
three-material decomposition of soft tissue, air, and iodine. This showed the 
distribution of iodine in the whole left ventricle (LV) myocardium. 
Color-coded iodine maps were also made then merged with corresponding 
CT images. Soft-tissue settings were used to create fusion images. This 
allowed simultaneous depiction of myocardium and myocardial delayed 
contrast-enhancement. All images were reconstructed on short axis plane. 
For image analysis, reconstructed iodine maps and merged color-coded 
iodine maps were transferred to a picture archiving and communication 
system (PACS) (Centricity 1.0; GE Medical Systems, Mt Prospect, IL, 
USA).
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6. MRI protocol
MRI was performed within 2 hours of dual-energy CT. MRI 
imaging was performed using a 3.0-T MR scanner (Magnetom Trio Tim, 
Siemens Healthcare, Erlangen, Germany) with a 6 channel anterior body 
matrix coil and 12 channel posterior head matrix coil. Localization of the 
heart was performed with steady state free precession sequence under ECG 
gating. Cine, late gadolinium enhancement (LGE), pre- and post-contrast T1 
mapping images were acquired. For cardiac functional analysis, cine images 
were acquired using a TrueFISP sequence in a short-axis plane orientation 
using the following parameters: TR = 3.9 ms, 
TE = 1.68 ms, flip angle = 50°, 25 phases, slice thickness = 3 mm, slice 
gap = 0.6 mm, acquisition matrix = 160 × 160, and a field of view = 150 
× 135mm2. T1 mapping was performed with a modified Look-Locker 
inversion recovery (MOLLI) sequence during the end expiratory period in a 
mid-ventricular short axis view-. For the MOLLI imaging, three 
nonselective inversion pulses; steady state free precession single-shot readout 
in mid-diastolic phase was employed using the following parameters: field 
of view = 150 × 121 mm, acquisition matrix = 192 × 155, slice thickness 
= 3.5 mm, TR = 3.6 ms, TE = 1.45 ms, minimum inversion time 105ms, 
inversion time increment 60 ms, flip angle = 35°, GRAPPA parallel 
acquisition factor = 2, four images are acquired after the first inversion 
pulse, followed by a pause of six heart beats, then four images are 
acquired after the second inversion pulse, followed by a pause of six heart 
beats, then six images are acquired after a third inversion pulse. Fully 
automated non-rigid motion correction was applied to register the individual 
TI images before inline T1fitting was performed using a mono-exponential 
3-parameter fit. Pre-T1 mapping images were acquired before the injection 
of contrast. Post-contrast T1 mapping images were acquired 13 minutes 
after the injection of a 0.2 mmol/kg intravenous dose of gadolinium 
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contrast agent (Omniscan®; GE Healthcare, Princeton, NJ). LGE MR 
imaging was obtained 15min after the injection of the contrast agent using 
a magnitude- and phase-sensitive inversion recovery (PSIR) prepared steady 
state free precession sequence, with the inversion time adjusted to null the 
normal myocardium. LGE images were obtained along the same axis plane, 
and with the same slice thickness as used for the T1 mapping images (TR 
= 3.3 ms, TE = 1.41 ms, FOV = 200 × 162mm2, thickness 3.5 mm, 
matrix = 224 × 201, non-selective inversion recovery, flip angle = 70º, BW 
770 Hz/pixel, number of trigger pulses = 2). The appropriate inversion time 
prior to LGE MR imaging was determined using a steady state free 
precession sequence with varying inversion times from 150 to 650 ms to 
null the signal from the normal myocardium.
7. Image analysis 
Two radiologists (Y.J.H., C.H.P.) with nine years of experience in 
cardiovascular image interpretation analyzed all CT, MR images each other 
and interobserver agreement was assessed. 
 A. CT image analysis
  (A) CT image analysis for the measurement of CT ECV (%)
CT ECV (%) was measured on a PACS system. We chose one 
image at mid LV where papillary muscles were visible from the 13 minute 
iodine map images reconstructed on the short axis plane. The selected 
image was used for a regional analysis of LV myocardium. The regions of 
interest (ROI) were drawn at the septal segment as large as possible and 
round ROI larger than 10-15mm2 was drawn in LV cavity avoiding 
papillary muscle (Fig. 2a). Mean attenuation in HU at ROI was recorded. 
Myocardial CT ECV (ECVm) was calculated by using the following 
formula.
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ECVm = (HUm/HUb) × (1－Hct), 
where ECVm = myocardial ECV in dual-energy CT, HUm = HU of ROI of 
myocardium on the iodine map, HUb = HU of blood pool on the iodine 
map, Hct = hematocrit value.
(a)                    (b)                    (c)
Figure 2. Measurement on CT and MRI: short axis cardiac images were used to 
define the region of interest (ROI) for fibrosis in the rabbit control and 
experimental groups.
(a) The ROI on CT was drawn at the septal segment of the LV and LV cavity on 
the iodine map
(b) The ROI on the pre-contrast MR image was drawn at the same septal segment 
of the LV and LV cavity as the CT. 
(c) The ROI on the post-contrast MR image was drawn at the same septal 
segment of the LV and LV cavity as the CT, and the pre-contrast MR 
image.
 (B) CT ECV map software development
In this study, CT ECV map were quantified by a custom-developed 
software package written in MATLAB (Version 2014a, The MathWorks, 
Inc., Natick, Massachusetts, United States). This software package is 
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semi-automated GUI (Graphical User Interface), and it takes less than 10 
seconds using 2.3GHz Intel Core i7 computer with 8GB RAM running 
Mac OSX 10.9 for all processing steps. This software calculated ECV 
values based on the same equation mentioned above, and provided 
color-coded ECV maps of the whole myocardium. We exported iodine map 
images from PACS system with the DICOM (Digital Imaging and 
Communications in Medicine) file format. We reconstructed these DICOM 
images into one volume file (.vol extension), which contained all the slices. 
Then, we loaded this volume file on the software, and checked all the 
slices to find the blood pool area for ECV maps. We drew a blood pool 
ROI (region of interest) manually, and also input the hematocrit value 
required for ECV calculation. After this step, the software calculated ECV 
values and ECV maps of each slice, which were depicted on a color-coded 
map with a percentage scale. Additionally, we used each slice’s ECV value 
to make an ECV profile table to illustrate the ECV changes between slices.
(C) Evaluation of the image quality of CT iodine map 
Image qualities of the iodine maps scanned at 3, 5, 7, 9, 11, 13 
and 20 minutes after contrast injection were determined using subjective 
four-point scales (Fig 3). 4 = excellent, no image degradation, clear 
demarcation between left ventricle myocardium and cavity; 3 = good, minor 
degree of image degradation without affecting diagnostic accuracy; 2 = 
adequate, moderate degree of image degradation slightly affecting diagnostic 
accuracy, however, images were still used for diagnosis; 1 = poor, severe 
image degradation which greatly affected diagnostic accuracy, and resulted 
in non-diagnostic poor images.
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(a)
(c) (d)
(b) 
Figure 3. The four scales of image quality of the iodine maps    
(a) Image quality score 4; excellent, no image degradation, clear 
demarcation between left ventricle myocardium and cavity
(b) Image quality score 3; good, minor degree of image degradation 
without affecting diagnostic accuracy
(c) Image quality score 2; adequate, moderate degree of image degradation 
slightly affected diagnostic accuracy
(d) Image quality score 1; poor, severe image degradation which greatly 
affected diagnostic accuracy
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B. MR image analysis
(A) Functional analysis 
All MR cine images were transferred to a commercially available 
software (Argus; Siemens Medical Solutions, Erlangen, Germany). The 
function of the LV was assessed using Simpson' method on short-axis cine 
MR images. The endocardial and epicardial borders of the LV wall were 
delineated semiautomatically on the end-diastolic and end-systolic images. 
The papillary muscles and trabeculations were excluded from LV 
myocardium. LV end-diastolic volume (LVEDV) and LV end-systolic 
volume (LVESV) were automatically measured. LV ejection fraction (LVEF, 
%) is calculated as follows: 
LVEF (%) = 100 × (LVEDV－LVESV)/ LVEDV17,18
(B) MRI image analysis for the measurement of MR ECV fraction (%)
All MR images were transferred to a PACS system for image 
analysis. To quantify MR ECV, short axis plane pre-and post-contrast T1 
mapping images were needed. We selected one pre- and one post-contrast 
T1 mapping image at mid LV where papillary muscles were visible. On 
those images, the same septal segment measured on CT was selected and 
the region of interests (ROIs) were drawn. For a measurement of T1 value 
of blood, the round ROI larger than 10-15 mm2 was drawn in LV cavity 
avoiding papillary muscles (Fig 2b-c). The ECV fraction of myocardium 
was calculated from the equation using Hct, pre-and post-contrast T1 values 
of myocardium and LV blood as follows.
ECV = [(1/T1post-contrastmyocardium)－(1/T1pre-contrastmyocardium)]
/[(1/T1post-contrastblood)－(1/T1pre-contrastblood)] × (1－Hct)
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8. Histologic analysis
For histologic analysis, samples from left ventricle were obtained 
immediately after euthanasia using KCl injection. And the heart was fixed 
in 10% paraformaldehyde buffered with phosphate. After 1 week of 
fixation, the tissue was dissected into short axis plane at mid LV level, 
where papillary muscles were visible, using rabbit heart slicer (Zivic 
instruments, Pittsburg, PA, USA). The fragments were dehydrated in 
solutions of decreasing concentration of alcohol, cleared in xylene and 
embedded in paraffin. Three micrometers section were obtained and stained 
with picrosirius red stain. 
A. Collagen volume fraction (CVF,%) analysis 
An independent researcher performed the histopathologic analysis 
while blinded to the CT and MRI results. Each histopathologic section was 
obtained at the septal segment at mid LV. Next, the section was digitally 
photographed with high-power magnification (×200) and transferred to the 
computer. The histopathological image analysis was performed with ImageJ 
(National Institute of Health, Bethesda, MD). First, the image was 
converted into 8 bit unsigned binary gray scale with tiff (Tagged Image 
File Format). Second, a histogram map was created for thresholding 
segmentation between fibrosis and myocardial cells. Normally, fibrosis is 
distributed on signal intensity scale of approximately 0 to 30 and 
myocardial cells are distributed on signal intensity scale of 200 to 255 on 
8 bit binary image. Third, segmentation was optimized by manipulating two 
thresholds at the location of pixel intensity 40 and 180. Based on these 
two values, the pixel numbers in these two areas were counted, and 
estimated the fibrosis to myocardium ratio (in percentage) on the image. 3 
images were assessed per model, and the mean percent fibrosis was 
obtained.
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9. Statistical Analysis
All continuous data are expressed as means ± standard deviations 
(SD) and categorical variables are presented as numbers or percentages. CT 
ECV, MR ECV at 13 minutes were compared with histologic CVF by 
Spearman correlation. The relationship between myocardial CT ECV and 
MR ECV at 13 minutes was also assessed by r using mixed model. We 
evaluated the change in CT ECV values according to the scan time, and 
the change in CT ECV and MR ECV according to modeling time (between 
control group, Group I-III) using a linear mixed model as implemented in 
the MIXED procedure of SAS (version 9.2; SAS Institute, Cary, NC, USA) 
with restricted maximum likelihood estimation. Agreement between these 
measures of CT, MR ECV between two observers was assessed by 
intraclass correlation coefficient (ICC). The Bland-Altman plot between CT 
ECV and MR ECV at 13 minutes was demonstrated. P value less than 
0.05 was considered to indicate statistical significance. All statistical 
analyses were performed with the Statistical Package for the Social Science 
(SPSS) software (Version 20; SPSS Inc., Chicago, IL, USA), SAS (Version 
9.2; SAS Institute Inc., Cary, NC, USA.) or MedCalc (Version 12.7.0; 
MedCalc Software, Ostend, Belgium)
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III. RESULTS
A total of fifteen control and eleven DCR models were included in 
this study. For the image analysis, CT, MR images of the 15 control 
models, 11 Group I (6-week DCR) rabbits and 8 Group II (12-week DCR), 
and 5 Group III (16-week DCR) rabbits were evaluated. For the histologic 
analysis, 4 control rabbits, 3 Group I (6-week DCR) rabbits and 3 Group 
II (12-week DCR), and 5 Group III (16-week DCR) rabbits were analyzed.
1. Physiological and functional data
The hemoglobin level at 6 weeks was seen significantly decreased 
in the DCR models compared to the control group. The initial hemoglobin 
level of control group was 42.0% (range, 33-55) and 6 week hemoglobin 
level was 33.2% (range, 19-46) (Table 1) In DCR model, ventricular 
chamber enlargement and left ventricular wall thinning is noted (Fig 4). 
The mean LVEF of post -modeling group II, III were significantly lower 
than control groups (Table 1).
Table 1. Physiological and functional data in all groups
Control
(Pre-model, 
n = 15)
Group I
(6 week DCR‡ 
, n = 11)
Group II
(12 week 
DCR, n = 8)
Group III
(16 week 
DCR, n = 5)
Hemoglobin (%)* 42.0 (33.0-55.0)
33.2
(19.0-46.0)
33.2 
(25.0-42.0)
36.1
(24.0-43.0)
Left ventricular ejection 
fraction (%)* 56.3 ± 6.4 41.6 ± 2.8 31.9 ± 15.3
† 36.7 ± 2.2†
End diastolic volume (㎖)* 2.25 ± 0.80 2.04 ± 0.70 2.32 ± 0.56 3.08 ± 0.86
End   systolic volume (㎖)* 1.00 ± 0.43 1.19 ± 0.41 1.64 ± 0.77 2.02 ± 0.63
Stroke volume (㎖)* 1.24 ± 0.39 0.85 ± 0.29 0.69 ± 0.22 1.19 ± 0.46
Cardiac output (㎖/min)* 0.20 ± 0.86 0.11 ± 0.05 0.08 ± 0.04 0.05 ± 0.10
Left ventricle mass (g)* 2.53 ± 0.60 2.65 ± 0.72 3.15 ± 0.75 3.52 ± 0.44
* Mean ± SD, † p < 0.05, statistically significant 
‡ DCR = dilated cardiomyopathy rabbit model
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(a)                            (b)
(c)                            (d)
(e)
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Figure 4. The comparision of CT axial, 4-chamber cine MR, and LGE MR 
image of left ventricle  before and 16 weeks after modeling
(a-b) CT axial image (a), and 4-chamber cine MR image (b) of a control 
model ,left ventricle ejection fraction = 53.5%
(c-e) CT axial image (c), and 4-chamber cine MR image (d), and the LGE 
MR image (e) of 16 week DCR model, left ventricle ejection fraction = 
36.7%; Left ventricular systolic function decreased and left ventricular 
globular dilatation and wall thinning is noted. On the LGE MR image, 
there was no focal delayed enhancement on LV myocardium.
2. Histological data
On picrosirius red stain, the area stained red represented collagen 
fibers located in the extracelluar space. The collagen volume fraction (CVF) 
of a 6-week model showed a mild increase compared to the control model. 
The CVF increased again between the 6-week and 12-week models. There 
was a dramatic increase in the CVF between 12-week, and 16-week models 
(Fig 5). 
The histological examples of control, group I-III demonstrate (a) 
2.5%, (b) 5.0%, (c) 24.9%, and (d) 44.7% CVF (Fig 6). Mean CVF of 
control group (n = 4) was 2.6% (range, 2.0-3.3). That of group I (n = 3), 
group II (n = 3), group III (n = 5) were 10.6% (range, 4.7-21.9), 21.5% 
(range, 10.7-37.7), 48.3% (range, 24.6-67.2) (Fig 5). The difference between 
group III and group II was larger than that of group II and group I. The 
graph shows that fibrosis was more accelerated as time went.
(a) 
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Figure 5. Mean histological collagen volume fraction (CVF,%) in control 
and group I-III
                                     
(b)
    
(c)
    
(d)
Figure 6. The histological example of control, group I-III
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The histological example of control, group I-III demonstrate (a) 
2.5%, (b) 5.0%, (c) 24.9%, and (d) 44.7% CVF, each other (picrosirius 
red: original magnification ×200.)
3. CT and MRI data
A. Validation of CT protocol and evaluation of image quality
To determine the proper scanning and find the stabilized point of 
CT ECV, we scanned once then three minutes later, thereafter every two 
minutes until 20 minutes. CT showed no significant change from 3 minutes 
to 20 minutes in all groups (control group: p = 0.081, post-modeling 
group: p = 0.991, all groups: p = 0.940) (Fig 7a-c). A total of 254 septal 
segments were analyzed in all groups. Of these, 238 (93.7%) segments 
were diagnostic (score = 2-4):  excellent (score = 4) in 61 (24.0%) 
segments, good (score = 3) in 106 (41.7%) segments, adequate (score = 2) 
in 71 (28.0%) segments, and 16 (6.3%) segments were nondiagnostic (score = 1). 
(a) 
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(b) 
(c) 
Figure 7. The change of CT ECV over time after contrast injection
(a) The change of CT ECV over time after contrast injection in control 
group (p = 0.081)
(b) The change of CT ECV over time after contrast injection in 
post-modeling groups (group I-III) (p = 0.991)
(c) The change of CT ECV over time after contrast injection in all rabbits 
(p = 0.940)
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B. CT and MR ECV
The mean CT ECV of control group (n = 15) was 28.5% (range, 
25.9-31.3). Those of group I-III were 35.3% (range, 30.2-40.1), 41.9% 
(range, 35.6-44.1), 42.1% (range, 39.2-46.4). The mean MR ECV of control 
group (n = 15) was 28.8% (range, 26.1-30.8). Those of group I-III were 
32.6% (range, 29.9-34.3), 35.8% (range, 31.0-39.8), and 41.3% (range, 
38.4-47.3) (Fig 8, Table 2). The interobserver agreement for CT, MR ECV 
measurements was good (ICC (95% CI), 0.902 (0.920-0.947) for CT ECV; ICC, 
0.953 (0.911-0.975) for MR ECV). Bland-Altman plot between CT ECV and 
MR ECV at 13 minutes was demonstrated at Figure 9.
Figure 8. Comparison of CT and MR ECV between control 
and group I-III
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Table 2. CT, MR extracellular volume (ECV) and histologic collagen 
volume fraction (CVF) in all groups
Control
 (Pre model, 
n = 15)
Group I
 (6 week DCR
†, n = 11)
Group II 
(12 week DCR, 
n = 8)
Group III
 (16 week 
DCR, n = 5)
CT ECV (%)*
28.5
(25.9-31.3)
35.3
(30.2-40.1)
41.9‡
(35.6-44.1)
42.1§
(39.2-46.4)
MR ECV (%)*
28.8
(26.1-30.8)
32.6
(29.9-34.3)
35.8‡
(31.0-39.8)
41.3§
(38.4-47.3)
CVF (%)*
2.6ǁ
(2.0-3.3)
10.6¶
(4.7-21.9) 
21.5¶
(10.7-37.7)
48.3§#
(24.6-67.2)
* Mean (range)
† DCR = dilated cardiomyopathy rabbit model
‡ Control vs. Group II, p < 0.05, statistically significant 
§ Control vs. Group II, p < 0.05, statistically significant 
ǁ n = 4, ¶ n = 3, # n = 5
Figure 9. Bland-Altman Comparison of CT ECV and MR ECV
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C. Comparison between CT, MR ECV and histologic collagen volume 
fraction 
CT ECV measured with dual-energy CT correlated with histologic 
CVF (n = 15, r = 0.811, p < 0.001) and MR ECV correlated with 
histologic CVF (n = 15, r = 0.946, p < 0.001). There was good 
correlation between CT ECV and MR ECV in all groups (n = 26, r = 
0.888, p < 0.001), and post-modeling groups (n = 11, r = 0.840, p < 0.001 )
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IV. DISCUSSION  
The aims of this study were to validate ECV fraction using 
dual-energy CT and to compare it with contrast-enhanced MRI and 
histologic findings. We have demonstrated a DCR model for radiologic and 
histological evaluation of diffuse myocardial fibrosis. A previous study 
reported that after administration of doxorubicin at the dose of 1 mg/kg 
twice a week for only 6 weeks is safe and sufficient to induce dilated 
cardiomyopathy in rabbits with low mortality rate.19 We followed the same 
methods to make DCR models. However, initially the mortality was 
unexpectedly high. Among the twelve rabbits, five rabbits were dead before 
6 weeks. The reason was probably that quarantine equipment was not 
available. So we did nutritional supports with kale and cabbage every day 
and added intramuscular injection of antibiotics every day from 5 weeks 
after modeling. Recently, myocardial fibrosis imaging based on T1-mapping 
and ECV measurement is regarded as a promising tool to detect and 
quantify diffuse myocardial fibrosis, which can overcome the limitation of 
LGE imaging. The usefulness of T1 mapping MR imaging for 
quantification of diffuse myocardial fibrosis is demonstrated in various 
cardiac diseases.8,9,20-27 Flett et al. reported a new MRI method using a 
concept of extracellular volume fraction to assess diffuse myocardial fibrosis 
using equilibrium contrast MRI.1 ECV has been proven to be reliable and 
reproducible parameters with less MRI parameters influenced by other 
confounding factors such as scan timing, concentration of contrast, field 
strength, different vendor platforms, and patients’ renal function status.2,28,29 
However, MR has a few limitations such as motion correction, 
different scan position between pre- and post-contrast T1 mapping images, 
incomplete coverage of the heart, variable confounding factors affecting 
post-contrast T1 value.2,30,31 etc. Most recently, Nacif et al.12,13 reported the 
usefulness of measurement of myocardial ECV using bolus injected contrast 
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enhanced CT. They recruited 24 heart failure patients. ECVs of cardiac CT 
and MR were higher in patients than healthy controls. There was good 
correlation between ECV of cardiac CT and cardiac MR imaging ECV 
values (r = 0.82, p < 0.001). Of note, the radiation dose was not high 
(1.98 mSV ± 0.16).12 In another study, Bandula et al.11 developed and 
validated equilibrium contrast-enhanced CT using continuous infusion after 
bolus injection protocol and compared with ECV from equilibrium 
contrast-enhanced magnetic resonance imaging and histologic reference. 
Equilibrium CT ECV was strongly correlated to equilibrium MR ECV    
(r = 0.73) and also showed a significant correlation with histologic fibrosis 
(r = 0.84, p < 0.001). These studies showed the possibility of quantification 
of myocardial fibrosis using cardiac CT. CT has many advantages over MR; 
covering the whole myocardium in a short scanning time, low price, short 
scanning time, simultaneous evaluation of coronary arteries, etc. The 
previous study used conventional CT with both of pre-contrast and 
post-contrast equilibrium CT.11-13 For the analysis, ROI of myocardial 
septum were selected on the post‑contrast image and the matching 
pre-contrast image was selected by visual estimation. This method had 
misregistration errors due to changes in acquisition location of pre- and 
post-contrast CT. More importantly radiation exposure is doubled. We were 
cautioned by the difficulties of misregistration artifacts encountered when 
using conventional CT, as well as using the idea of visual estimation to 
match up the post-contrast image and the matching pre-contrast image. In 
our study we shifted the method to dual-energy CT which works with data 
acquired at the time of the scan to produce both images. Dual-energy CT 
would give data from CT imaging done at two different X-ray spectra at 
the same time.16 The difference in material composition is shown because 
of different photon absorption rates being affected at the two spectra by 
the data.16,32 The major advantages of dual-energy CT over conventional CT 
in this study are lack of misregistration errors occurring from pre- and 
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post-contrast scannings with different scanning time, different position. An 
iodine map reconstructed by data with simultaneous acquisition of 100 and 
140 kVp contrast images through the one scan is sufficient to visualize 
myocardial perfusion, delayed contrast-enhancement dispense of two step 
pre- and post-contrast scannings. Our study is the first study assessing CT 
ECV using dual-energy CT. For validation of CT ECV values, we scanned 
repeatedly from 3 minutes to 20 minutes after the contrast injection. We 
demonstrated continuous CT ECV values without significant change. We 
used the 13 minute scan time image for the measurements for both CT 
ECV and MR ECV. We used the same equation as the previous CT ECV 
studies: (ΔHUm/‍ΔHUb) × (1-Hct), where ΔHU = HUpost－HUpre, which 
means the change of attenuation value (HU) between before and after 
administration of iodine contrast agents. On dual-energy CT measurement of 
HU of the ROI on the iodine map represents the degree of enhancement 
on the measured area. HU of the ROI on the iodine map is sufficient to 
measure ΔHU of myocardium or blood cavity. Therefore, the equation was 
changed to (HUm/HUb) × (1-Hct), where HUm = HU of ROI of 
myocardium on the iodine map, HUb = HU of blood pool on the iodine 
map. We created a home-made software program that both measured the 
CT ECV and generated a color-coded iodine map which illustrated the 
distribution of iodine contrast in myocardium at a glance. The reported HU 
on the iodine map quantified the myocardial enhancement. This pilot study 
has laid out the steps necessary to conduct a broader examination of the 
dual energy CT, MRI, versus histology assessment of fibrotic cardiac 
disease. Although MRI has been the standard for imaging fibrosis the 
potential benefits of CT usage need to be recognized. CT can allow for 
fast, available, and economical imaging. This study shows the proof of 
concept using an animal model. Further studies are suggested for 
assessment in humans, which to our knowledge has not been pursued yet. 
The limitations of our study include the small sample size, which 
- 29 -
prevents the generalization of the data. The second limitation was 
estimation of exposed radiation dose was not available because repetitive 
scannings were done every two minute to validate scan protocol. And the 
image qualities of the iodine maps were not good because of the increased 
number of artifacts. 71 segments (28%) were score 2 (good) which can 
slightly affect diagnostic accuracy and 16 segments (6.3%) were 
nondiagnostic (score 1: poor). It was thought that the motion artifacts were 
caused by the rabbits’ fast heart rate, and the low temporal resolution of 
dual energy CT. Although we used a drug to reduce heart rate, the mean 
heart rate of pre-modeling animal was 114.3 ± 29.5 and that of 
post-modeling rabbit was 98.2 ± 17.3. However, this problem will be 
solved if applied to humans, because the human heart rate is lower in 
comparison to rabbits. Lastly, we correlated CT ECV with histologic CVF. 
Because there is no direct method to measure histologic ECV, we could 
not compare the relationship between CT ECV and histologic ECV. 
However, the correlation between the CT ECV and histologic CVF was 
statistically significant. Further studies are suggested for assessment in 
humans in a clinical setting to determine the quantification of the ECV 
using dual-energy CT with low radiation exposure. 
V. CONCLUSION
This study demonstrates that dual-energy CT is a noninvasive 
feasible method to measure diffuse myocardial fibrosis quantitatively using 
CT ECV without misregistration errors with lower radiation exposure. 
Although MRI has been the standard for imaging fibrosis the potential 
benefits of CT usage need to be recognized. 
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<ABSTRACT(IN KOREAN)>
확장성 심근병증 토끼에서 이중에너지 전산화 단층 촬영술을 이용한 
심근 세포 외 부피 측정: 자기공명영상을 이용한 심근 세포 외 부피 및 
조직학적인 소견과 비교
<지도교수: 최 병 욱>
연세대학교 대학원 의학과
홍 유 진
최근 개발된 자기공명영상의 T1 지도화 기법은 이전 지연 조영 증강 
영상으로 영상화할 수 없는 미만성 심근 섬유화를 조기발견하고 
정량화할 수 있는 유용한 기법으로 자리 잡고 있다. 전산화 단층 
촬영술에서 이용하는 요오드 조영제가 자기공명영상에서 쓰이는 
가돌리늄 조영제가 이 세포 외 부피 조영제이며 비슷한 동역학을 
보인다는 이론에 근거하여 전산화 단층 촬영술로 세포 외 부피를 
정량화할 수 있음이 증명되었다. 따라서 본 연구 에서는 이중에너지 
전산화 단층 촬영술을 이용하여 심근 세포 외 부피를 측정하고 이를 
자기공명영상을 이용한 심근 세포 외 부피 값과 조직학적 섬유화 
정도와 비교하고자 하였다.
토끼에 독소루비신을 일주일에 2번씩 1.0 mg/kg 용량으로 정맥 
주입하여 심근 섬유화 모델을 제작하였으며 섬유화 모델을 만들기 전과 
만든 후 6주, 12주 16주에 이중에너지 조영 증강 전산화 단층 
촬영술과 자기공명영상 (조영 증강 T1 지도화 기법영상, 
영화영상기법영상)을 시행하였다. 전산화 단층 촬영과 자기공명영상 
촬영은 2시간이내 시행하였다. 자기공명 영화영상을 이용하여 좌심실 
기능을 측정하였으며 이중에너지 전산화 단층 촬영술을 이용하여 얻은 
요오드 지도와 T1 지도화 기법 자기공명영상으로 얻은 조영 전, 후 T1 
지도화 이미지를 이용하여 세포 외 부피를 측정하였다. 세포 외 부피는 
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심실 단축 면 영상 유두 근이 보이는 좌심실 중간 중격 부분에 
관심영역을 그려 측정하였으며 전산화 단층촬영 이미지와 자기 공명 
영상 이미지 상 최대한 동일한 부위에서 측정하였다.
총 15마리 토끼를 심근 섬유화 모델을 제작하기 전 전산화 단층 
촬영술과 자기공명영상을 촬영하였으며 이중 4마리는 정상토끼의 
조직학적 소견을 위해 희생하였다. 11마리의 심근 섬유화 모델을 
제작하였으며 모델링 후 6주 (n = 11), 12주 (n = 8), 16주 (n = 5) 
에 추가로 영상을 얻었다. 조직학적인 소견을 위해 6주 촬영 직후 
3마리, 12주 촬영 직후 3마리, 16주 촬영 직 후 5마리를 희생하여 
picrosirius red 염색 후 슬라이드를 제작하였다.
전산화 단층 촬영술을 이용한 요오드 지도에서 잰 세포 외 부피는 6주 
모델(11마리), 12주 모델(8마리), 16주 모델(5마리)에서 각각 28.5% 
(25.9-31.3), 35.3% (30.2-40.1), 41.9% (35.6-44.1), 42.1% 
(39.2-46.4), p < 0.001)로 점점 증가하는 양상을 보였고 자기공명 
영상에서 측정한 세포 외 부피와 높은 연관성을 보였으며 조직학적인 
섬유화 정도와도 높은 연관성을 보였다.
본 연구를 통하여 이중에너지로 얻은 세포 외 부피가 자기공명영상으로 
기법에서 얻은 세포 외 부피와 조직학적인 섬유화 정도와 높은 일치 
도를 보임을 증명하였으며 결론적으로 이중에너지 전산화 단층 
촬영술은 한 번의 스캔으로 오등록 오류 없이 심근 섬유화를 정량화할 
수 있는 비 침습적인 유용한 영상기법이다.
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